Physiomics PLC Contract Award
September 17 2024 - 2:00AM
RNS Regulatory News
RNS Number : 3146E
Physiomics PLC
17 September 2024
17 September 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to announce that it has been awarded a new
contract by an existing, large pharma client. The project involves
updating two models previously created for the client with newly
generated clinical data. These models are based on the Company's
proprietary Virtual Tumour platform and are developed to support
dosing and scheduling decisions for the client's oncology
combination therapies. The value of the contract is £65k and it is
anticipated that it will be completed over the course of the
current calendar year.
Dr Peter
Sargent, CEO, commented: "We are delighted to have been awarded this
new contract with one of our existing clients. This win is
testament to the quality and impact of the services we provide and
the longevity of our client relationships".
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
CNTEAPNKFFALEEA
Physiomics (LSE:PYC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Nov 2023 to Nov 2024